Document:

EX-10.1

 Exhibit 10.1 

***Text Omitted and Filed Separately 

with the Securities and Exchange Commission. 

Confidential Treatment Requested 

Under 17 C.F.R. Sections 200.80(b)(4) 

and 240.24b-2. 
 AMENDED
AND RESTATED NALTREXONE HYDROCHLORIDE SUPPLY AGREEMENT 
 This Amended and Restated Naltrexone Hydrochloride Supply Agreement (this
“Agreement”) is made effective as of January 1, 2015 (the “Effective Date”) by and among OREXIGEN THERAPEUTICS, INC. (“OREXIGEN”), a Delaware corporation located at 3344 N. Torrey Pines Court, Suite 200, La Jolla,
CA 92037, and MALLINCKRODT LLC (“MALLINCKRODT”), a Delaware limited liability company located at 675 McDonnell Blvd., Hazelwood, Missouri 63042. 

WHEREAS, MALLINCKRODT is a manufacturer of an active pharmaceutical ingredient known as Naltrexone Hydrochloride and MALLINCKRODT wishes to supply Naltrexone
Hydrochloride to OREXIGEN on the terms described herein; and 
 WHEREAS, OREXIGEN desires a supply of quantities of Naltrexone Hydrochloride and wishes to
purchase Naltrexone Hydrochloride from MALLINCKRODT on the terms described herein. 
 NOW, THEREFORE, in consideration of the mutual covenants set forth
herein, MALLINCKRODT and OREXIGEN (each, a “Party” and, collectively, the “Parties”) agree as follows. 
  

	1.	SCOPE OF AGREEMENT 

  

	1.1.	Subject to the provisions of this Section 1.1 below, this Agreement shall apply to all purchases of Naltrexone Hydrochloride by OREXIGEN and its Affiliates (as defined below in this Section 1.1) under this
Agreement from MALLINCKRODT during the Term (as defined below in Section 11.1). OREXIGEN (on behalf of itself and its Affiliates) agrees to purchase from MALLINCKRODT and MALLINCKRODT agrees to supply to OREXIGEN such amounts of Naltrexone
Hydrochloride as OREXIGEN shall order in accordance with the requirements hereof. During any applicable calendar year during the term of this Agreement, OREXIGEN agrees to purchase from MALLINCKRODT at least [*...***...] ([...***...]) of OREXIGEN’S commercial requirements for Naltrexone Hydrochloride for use in Finished Products intended for commercial sale in those jurisdictions set forth
on Schedule B attached hereto, provided that [...***...]. For purposes of this Agreement, an “Affiliate” of a Party shall mean and refer to any firm, person or entity that controls, is controlled by or is under common control
with such Party, where “control” means the power, by means of voting power, proxy or power in fact (by whatever means) to direct the business and operations of any firm, person or entity. 

 

	1.2.	 This Agreement does not constitute a purchase order. Purchases under this Agreement shall be made only with written purchase orders issued by OREXIGEN
to 

  
 * ***Confidential Treatment Requested 

	 	
MALLINCKRODT (each, a “Purchase Order”). No Purchase Order shall specify [*...***...]. Each Purchase Order shall set forth the
information required by and meet the requirements of Section 3.3. In the event of a conflict or inconsistency between the terms of any Purchase Order, order acknowledgement, invoice, shipping terms, packaging slip or other documentation issued
by either Party and the terms of this Agreement, the terms of this Agreement shall control and prevail in every case and any additional (except for purchased quantities, shipping and delivery dates) and/or inconsistent terms set forth in any other
document issued by either Party are hereby expressly rejected, unless such documentation specifically states that it overrides conflicting terms of and/or supplements the terms of this Agreement (as appropriate) and is signed by authorized
representatives of each of the Parties. 

  

	1.3.	All Naltrexone Hydrochloride sold by MALLINCKRODT to OREXIGEN will be manufactured by MALLINCKRODT in accordance with the terms of this Agreement. 

 

	2.	MANUFACTURING; SPECIFICATIONS; QUALIFICATION OF SECOND SOURCE 

 

	2.1.	The Naltrexone Hydrochloride supplied to OREXIGEN hereunder shall meet the release specifications set forth on Schedule A attached hereto (“Specifications”) at the time of delivery. All Naltrexone
Hydrochloride supplied hereunder will be manufactured in accordance with the methods, processes and procedures, including site of manufacture, set forth in MALLINCKRODT’s drug master file (“DMF”) or any equivalent issued under any
applicable laws, rules or regulations other than those of the United States (such as an Active Substance Master File or a Certificate of European Pharmacopeia, (such documents referred to as a “DMF Equivalent”) for Naltrexone
Hydrochloride. OREXIGEN shall have the right to review the [...***...] at OREXIGEN’s request. 

  

	2.2.	 There will be no changes made to the Specifications set forth on Exhibit A except with the mutual written agreement of the Parties; provided that,
MALLINCKRODT will use commercially reasonable efforts to implement any changes in Specifications requested by OREXIGEN if such changes would not require revalidation of the applicable manufacturing process. In the event any change in Specifications
requested by OREXIGEN would cause MALLINCKRODT to incur additional Direct Manufacturing Cost (as defined below in this Section 2.2), MALLINCKRODT shall notify OREXIGEN in writing, within [...***...] after the date of any requested
specification change by OREXIGEN, of the reason for and nature of any such increased cost and, if [...***...], MALLINCKRODT shall begin implementation of any such requested Specification change. In the event any change to the Specifications
requested by OREXIGEN is made, MALLINCKRODT shall perform, [...***...], all analytical and experimental work reasonably required to implement any such change, but OREXIGEN shall be responsible, [...***...], for filing all changes
proposed by OREXIGEN in connection with any regulatory approval, and for seeking approval of any such change required by any governmental agency, regulatory agency, commission or similar body of any domestic or non-domestic jurisdiction
(“Regulatory Agency”) with respect to OREXIGEN’s oral dosage formulation containing Naltrexone Hydrochloride (“Finished Product”). Notwithstanding the foregoing, the Parties

  
 * ***Confidential Treatment Requested 
 Confidential

 CSK/Orexigen –Mallinckrodt Amended & Restated Naltrexone Hydrochloride Supply Agreement 

  
 2 

	 	
acknowledge that it is possible that changes in applicable laws, or actions of the United States Food and Drug Administration (“FDA”) or any other Regulatory Agency may require changes
to be made in the Specifications. Should such an eventuality occur, the Party becoming aware of any required change will immediately notify the other Party in writing of the nature of and reason for any such potential Specification changes and such
changes will be implemented by MALLINCKRODT as and when required (but not earlier than required); provided, however, it is understood that [*...***...]. The term “Direct Manufacturing
Cost” shall mean all costs of [...***...] incurred with respect to [...***...], but shall not include [...***...]. Absent the requirements of applicable law, the FDA or any Regulatory Agency or the occurrence of any
circumstances covered by the language of [...***...]. 

  

	2.3.	MALLINCKRODT will notify OREXIGEN at least [...***...] in advance (unless a lesser time to implement any change is dictated by law) of any and all material changes in its production, testing or packaging
procedures in the DMF documented process as required by FDA’s “Guidance for Industry to an approved NDA or ANDA”. The parties acknowledge that the purpose of the immediately preceding sentence is to allow OREXIGEN a reasonable amount
of time to receive appropriate regulatory approval from the FDA or any other Regulatory Agency prior to MALLINCKRODT implementing a significant change to its DMF or any DMF Equivalent. 

 

	2.4.	MALLINCKRODT will [...***...] to enable OREXIGEN to secure from relevant Regulatory Agencies approval of MALLINCKRODT as a source of supply of Naltrexone Hydrochloride for OREXIGEN’s Finished Products.
MALLINCKRODT will be responsible for procuring and maintaining the DMF and DMF Equivalents related to Naltrexone Hydrochloride in those jurisdictions set forth on Schedule B attached hereto, [...***...]. MALLINCKRODT has filed the DMF
with the FDA and has provided the DMF’s reference number in writing to OREXIGEN. OREXIGEN, and OREXIGEN’s licensee(s) with respect to the Finished Product (each an “Orexigen Licensee”), shall have the right to reference the DMF
in its NDAs or INDs (or ANDAs, if applicable) and DMF Equivalents from Regulatory Agencies in jurisdictions outside the United States, and the right to access the [...***...]. 

 

	2.5.	 MALLINCKRODT shall test, or have tested, each lot of Naltrexone Hydrochloride shipped to OREXIGEN using the analytical testing methodologies which are
set forth in the Specifications in order to assure the conformity of each lot of Naltrexone Hydrochloride supplied hereunder to the Specifications and all applicable laws. With each

  
 * ***Confidential Treatment Requested 
 Confidential

 CSK/Orexigen –Mallinckrodt Amended & Restated Naltrexone Hydrochloride Supply Agreement 

  
 3 

	 	
shipment of Naltrexone Hydrochloride, MALLINCKRODT shall deliver to OREXIGEN certificates of analysis from MALLINCKRODT stating that the Naltrexone Hydrochloride being shipped has been tested and
does conform to the Specifications. 

  

	2.6.	Notwithstanding any other provision hereof, MALLINCKRODT’s obligation to supply and OREXIGEN’s obligations to purchase hereunder are [*...***...].
MALLINCKRODT will at all times [...***...] ensure that it has sufficient quota to perform its obligations hereunder. If MALLINCKRODT has insufficient quota to satisfy OREXIGEN’s requirements for Naltrexone Hydrochloride [...***...]
and the requirements of its other customers, MALLINCKRODT shall [...***...]; provided that MALLINCKRODT shall continue to be obligated to provide to OREXIGEN the amounts set forth in the Rolling Forecast most recently provided to OREXIGEN and
acknowledged and agreed to by an authorized representative of MALLINCKRODT. 

  

	3.	FORECASTS; FIRM COMMITMENT; PURCHASE ORDERS 

  

	3.1.	Initial Forecast. The initial forecast of the quantities of Naltrexone Hydrochloride that may be ordered by OREXIGEN, [...***...] is set forth on Schedule D attached hereto. MALLINCKRODT is obligated to
supply at least [...***...] percent ([...***...]%) of Naltrexone Hydrochloride ordered by OREXIGEN pursuant to any Purchase Order up to the quantities set forth for [...***...] in such initial forecast. 

 

	3.2.	 Rolling Forecasts. On or prior to the beginning of each [...***...] occurring during the Term following the initial forecast provided under
Section 3.1, OREXIGEN shall provide to MALLINCKRODT [...***...] rolling forecast of the quantities of Naltrexone Hydrochloride that may be ordered by OREXIGEN, by [...***...] (the “Rolling Forecast”). The first
[...***...] of each Rolling Forecast shall constitute a binding order on MALLINCKRODT and OREXIGEN for the quantities of Naltrexone Hydrochloride specified therein, and MALLINCKRODT shall be obligated to supply and OREXIGEN shall be obligated
to purchase no less than one hundred percent (100%) of the quantity of Naltrexone Hydrochloride ordered by OREXIGEN pursuant to any Purchase Order in such first [...***...]. The subsequent [...***...] of each Rolling Forecast shall
be non-binding estimates and shall be used by MALLINCKRODT for planning purposes only. Within a [...***...] period after the submission by OREXIGEN of any Rolling Forecast, MALLINCKRODT will review such Rolling Forecast to assess the
feasibility of production and supply of the amounts of Naltrexone Hydrochloride set forth in such Rolling Forecast. After such review (and in no event later than [...***...] after the submission of any such Rolling Forecast by

  
 * ***Confidential Treatment Requested 
 Confidential

 CSK/Orexigen –Mallinckrodt Amended & Restated Naltrexone Hydrochloride Supply Agreement 

  
 4 

	 	
OREXIGEN), MALLINCKRODT will advise OREXIGEN in writing of the results of its review, specifying whether or not MALLINCKRODT is able to meet the timing and volumes set forth in such Rolling
Forecast. If MALLINCKRODT indicates that it is not able to meet the timing and volumes set forth in such Rolling Forecast, the parties will [*...***...]. Whether based on agreement of the
Parties as contemplated in the immediately preceding sentence or based on MALLINCKRODT’s acknowledgement of the Rolling Forecast submitted by OREXIGEN, OREXIGEN shall timely submit to MALLINCKRODT Purchase Orders consistent therewith and
otherwise meeting the requirements hereof. MALLINCKRODT shall be obligated to supply and OREXIGEN shall be obligated to purchase no less than one hundred percent (100%) of the quantity of Naltrexone Hydrochloride ordered by OREXIGEN pursuant to
any Purchase Order which complies with this Section 3.2. 

  

	3.3.	Each Purchase Order submitted by OREXIGEN hereunder shall specify the quantity of Naltrexone Hydrochloride ordered, the total Price (as defined in Section 5.1) for such quantities of Naltrexone Hydrochloride
calculated in accordance with Section 5 hereof, and the required delivery date and destination, consistent with the terms of this Agreement. OREXIGEN shall submit each Purchase Order to MALLINCKRODT at least [...***...] in advance of the
delivery date requested in the Purchase Order. Within [...***...] after the date that a Purchase Order is submitted, MALLINCKRODT shall acknowledge receipt of OREXIGEN’s Purchase Order and confirm acceptance of such Purchase Order, if
issued in accordance with the requirements hereof. For the avoidance of doubt, [...***...] shall be obligated to [...***...]. 

  

	3.4.	During any period during this Agreement in which MALLINCKRODT, for any reason (including, without limitation, an event of force majeure as provided in Section 13.1), fails to deliver the requisite quantities of
Naltrexone Hydrochloride included in any accepted Purchase Order which complies with Section 3.1, Section 3.2, Section 3.3, and Section 4.1, within [...***...] after the date of delivery confirmed in writing by MALLINCKRODT
or if MALLINCKRODT otherwise notifies OREXIGEN that it will be unable to make delivery of all or a portion of the ordered Naltrexone Hydrochloride within [...***...] after the confirmed date of delivery, then OREXIGEN may refuse such late
shipment of Naltrexone Hydrochloride from MALLINCKRODT and purchase such quantities elsewhere. 

  

	3.5.	 By no later than [...***...], MALLINCKRODT will (a) establish and maintain an inventory reserve of Naltrexone Hydrochloride approximately
equal to [...***...] and (b) hold a reserve of [...***...] of Noroxymorphone as an intermediate that is able to be converted into Naltrexone Hydrochloride. Such minimum quantities required to be maintained and held by MALLINCKRODT
will be reviewed quarterly at the Parties’ business review meetings with the understanding that the 

  
 * ***Confidential Treatment Requested 
 Confidential

 CSK/Orexigen –Mallinckrodt Amended & Restated Naltrexone Hydrochloride Supply Agreement 

  
 5 

	 	
Parties’ intent is to have such quantities be equivalent to [*...***...] of forward demand; provided that any adjustments to such
minimum required quantities and/or the timing to achieve any such adjustments will require the mutual written agreement of both Parties. Subject to the terms and conditions of this Agreement and in particular any agreement between the Parties
arrived at in accordance with the immediately preceding sentence, OREXIGEN agrees to purchase [...***...] reserved inventory within [...***...] after it has been established and MALLINCKRODT will replace any purchased amounts
[...***...]. Naltrexone Hydrochloride from any reserved inventory will be shipped to OREXIGEN or its contract manufacturer on a [...***...] basis. 

  

	4.	DELIVERY 

  

	4.1.	Each Purchase Order shall specify the quantity of Naltrexone Hydrochloride ordered and the required delivery date and destination, consistent with the terms of this Agreement. Deliveries must be made on normal business
days of the designated facility unless otherwise coordinated. 

  

	4.2.	Subject to any written agreement between OREXIGEN and MALLINCKRODT to the contrary, MALLINCKRODT shall make all necessary shipping arrangements to OREXIGEN’s designated facility. Freight terms shall be as set forth
in Schedule C. Title to the Naltrexone Hydrochloride shall pass from MALLINCKRODT to OREXIGEN upon [...***...]. 

  

	4.3.	If and as applicable, OREXIGEN shall be responsible for coordinating any export of Naltrexone Hydrochloride from the United States and for coordinating any import of ordered Naltrexone Hydrochloride to countries outside
the United States to OREXIGEN’s designated manufacturing facilities, in either case in compliance with all applicable laws. MALLINCKRODT shall notify OREXIGEN of the expected delivery date of any Purchase Order to enable receipt to be
coordinated. 

  

	4.4.	Subject to clearance by customs (if applicable), all ordered Naltrexone Hydrochloride shall be delivered to OREXIGEN’s designated facility in MALLINCKRODT’s normal packaging and with typical accompanying
documentation for Naltrexone Hydrochloride, including, without limitation, in accordance with any procedures reflected in MALLINCKRODT’s DMF, provided that any such packaging and documentation shall meet the customs and regulatory requirements
of the United States and, as applicable, the location of OREXIGEN’s designated facility for delivery. Each shipment shall include certificates of analysis, and such other documentation and information as may be necessary for complying with all
applicable laws. 

  

	5.	PRICE AND PAYMENT 

  

	5.1.	The initial price for the Naltrexone Hydrochloride to be purchased by OREXIGEN hereunder is set forth in Schedule C, [...***...]. 

  
 * ***Confidential Treatment Requested 
 Confidential

 CSK/Orexigen –Mallinckrodt Amended & Restated Naltrexone Hydrochloride Supply Agreement 

  
 6 

	5.2.	In addition to the Price adjustments [*...***...], MALLINCKRODT shall be entitled to adjust the Price at any time during the Term [...***...] by giving
[...***...] prior written notice to OREXIGEN solely to take into account any documented and verifiable increases or decreases in the costs of manufacturing Naltrexone Hydrochloride resulting from changes in MALLINCKRODT’s manufacturing
processes in response to any [...***...], other than as a result of [...***...] (“Regulatory Price Change”). In the event of a [...***...], the Price shall be increased by an amount equal to the documented incremental
cost increase directly associated with the [...***...]. Notwithstanding any other provision hereof, any Price adjustment pursuant to [...***...] shall be implemented in such a manner as to ensure that no element of cost increase or
decrease is being duplicated in calculating the Price to be charged. 

  

	5.3.	MALLINCKRODT agrees to keep complete and accurate books and records with respect to costs of commercial manufacture of Naltrexone Hydrochloride for a minimum period of [...***...] after the calendar year in which
they are prepared, or for such longer period as may be required by applicable law. 

 MALLINCKRODT will provide to OREXIGEN
[...***...] reports [...***...] showing [...***...]. 
  

	5.4	MALLINCKRODT shall issue invoices to OREXIGEN at the time of shipment of any Naltrexone Hydrochloride. Each invoice shall set forth the applicable Price and all freight charges for the shipment properly determined in
accordance with the provisions of this Agreement. Payment of the invoice by OREXIGEN shall be within [...***...] following [...***...], subject to any amounts disputed in good faith by OREXIGEN. Payment shall be subject to the inspection
and acceptance procedures set forth in Section 6. All invoices and payments shall be in U.S. Dollars. 

  

	6.	INSPECTION, ACCEPTANCE AND REJECTION 

  

	6.1.	 If OREXIGEN reasonably determines that any Naltrexone Hydrochloride delivered hereunder does not comply with the Specifications, is adulterated, is
not manufactured in accordance with the provisions of this Agreement or is otherwise defective (Naltrexone Hydrochloride satisfying any of the foregoing known as “Defective Product”), then OREXIGEN may reject any such Naltrexone
Hydrochloride. At the time of any such rejection, OREXIGEN shall provide MALLINCKRODT with a written notice describing in detail the circumstances surrounding the rejection and OREXIGEN’s reasons therefor (“Rejection Notice”),
accompanied by such supporting documentation as shall be reasonably necessary to demonstrate the basis for any rejection. If OREXIGEN properly rejects any such Naltrexone Hydrochloride, it will, [...***...] option, either return the rejected
Naltrexone Hydrochloride to MALLINCKRODT or destroy or dispose of it in the least expensive and most environmentally sound manner. In any event, 

  
 * ***Confidential Treatment Requested 
 Confidential

 CSK/Orexigen –Mallinckrodt Amended & Restated Naltrexone Hydrochloride Supply Agreement 

  
 7 

	 	
MALLINCKRODT shall be responsible for the costs of any such return, destruction or disposal if such Naltrexone Hydrochloride has been properly rejected. It is understood that [*...***...] hereunder in the event of Defective Product it has properly rejected will [...***...]. Any Naltrexone Hydrochloride received by OREXIGEN from MALLINCKRODT that has not been
rejected by OREXIGEN within [...***...]. Notwithstanding the preceding provisions of this Section 6.1, [...***...]. 

  

	6.2.	Notwithstanding the preceding Section 6.1, [...***...], the Parties shall attempt to resolve any disagreement they have regarding the [...***...]. 

 

	6.3.	Notwithstanding the preceding provisions of this Section 6, in no event shall [...***...]. 

  

	7.	CONFIDENTIALITY 

  

	7.1.	 During the Term, the Parties may disclose certain confidential and proprietary information and data to each other relating to their respective
products (including active pharmaceutical ingredients and finished products) and businesses, (including, but not limited to financial and other business information, product samples, formulas, manufacturing processes, specifications, drawings,
schematics and other technical, customer and product development plans, forecasts, strategies and other data). Except as otherwise specifically provided herein, all information disclosed by one Party (in such capacity, the “Disclosing

  
 * ***Confidential Treatment Requested 
 Confidential

 CSK/Orexigen –Mallinckrodt Amended & Restated Naltrexone Hydrochloride Supply Agreement 

  
 8 

	 	
Party”) to the other Party (in such capacity, the “Receiving Party”) relating in any manner to the Disclosing Party’s products and/or its business shall constitute
“Proprietary Information.” 

  

	7.2.	Proprietary Information disclosed by a Disclosing Party to a Receiving Party hereunder shall be used by the Receiving Party solely in connection with exercising its rights or performing its obligations under this
Agreement. 

  

	7.3.	In consideration of the Disclosing Party’s disclosure and supply of Proprietary Information, each Party agrees, as a potential Receiving Party, that, for the Term and for a period of [*...***...] thereafter, it shall not disclose or use for any purpose other than as specified in Section 7.2 above, without the express prior written consent of the Disclosing Party, any
Proprietary Information, including any information concerning this Agreement or the interest of the Disclosing Party in exploring the possibility of entering into a business relationship with the Receiving Party, to any person other than to those
employees, consultants or agents of the Receiving Party (“Representatives”) who will be involved in fulfilling the Receiving Party’s obligations under this Agreement, provided that such Representatives have been made aware of the
obligations set forth in this Section 7. In any event, it is understood that each Party shall be fully responsible and liable for any improper use or disclosure of the other Party’s Proprietary Information by any of its Representatives.
Notwithstanding the foregoing, (a) OREXIGEN may disclose the existence and terms of this Agreement to bona fide potential investors, acquirers, corporate partners and financial advisors and (b) MALLINCKRODT may disclose the existence and
terms of this Agreement to bona fide potential investors, corporate partners and financial advisors. With respect to OREXIGEN, the term “Representative” shall also include any Orexigen Licensee, provided that OREXIGEN may disclose
Proprietary Information of MALLINCKRODT to such Orexigen Licensee only (i) to the extent such Orexigen Licensee is required to use such information in regulatory filings for the Finished Product, (ii) for quality assurance purposes to the
extent Orexigen supplies Finished Product to such Orexigen Licensee, (iii) concerning a complaint, claim, adverse reaction report or notice as described in Section 8.10, and/or (iv) in connection with an inquiry from the FDA or other
Regulatory Authorities as described in Section 8.5 and such Orexigen Licensee shall have the right to use such Proprietary Information only in connection with the foregoing activities. 

 

	7.4.	Each Party, as a potential Receiving Party, agrees to advise those of its Representatives who receive Proprietary Information (and such other persons who may receive Proprietary Information as permitted by the last
sentence of Section 7.3 above) that such information (a) is proprietary and confidential to the Disclosing Party and (b) shall not be disclosed to anyone except as authorized herein. Each Party further agrees to take such reasonable
precautions as it normally takes with its own confidential and proprietary information to prevent unauthorized disclosure or use of such Proprietary Information by anyone receiving it. 

 

	7.5.	 In the event that the Receiving Party is required by any government regulation, law, court order or rule or otherwise becomes legally compelled to
disclose any Proprietary Information, it will provide the Disclosing Party with prompt advance notice in writing (if 

  
 * ***Confidential Treatment Requested 
 Confidential

 CSK/Orexigen –Mallinckrodt Amended & Restated Naltrexone Hydrochloride Supply Agreement 

  
 9 

	 	
legally possible under the circumstances) so that the Disclosing Party may, at its discretion and at its own expense, reasonably intervene prior to disclosure. The Receiving Party will exercise
commercially reasonable efforts to obtain reliable assurance that confidential treatment will be accorded to such Proprietary Information. 

  

	7.6.	Notwithstanding any of the foregoing provisions of this Section 7, the term “Proprietary Information” and the obligation of confidentiality associated therewith shall not apply to the following
information: (a) information which, at the time of the Disclosing Party’s disclosure to the Receiving Party, is publicly known or has been made publicly available, (b) information which, after the Disclosing Party’s disclosure to
the Receiving Party, becomes publicly known or available, except where such knowledge or availability is the result of the Receiving Party’s breach of this Agreement or otherwise is the result of any unauthorized disclosure by any of its
Representatives, (c) information which, prior to the Disclosing Party’s disclosure to the Receiving Party, was already in the Receiving Party’s possession, as evidenced by its prior written records, or (d) information which,
subsequent to the Disclosing Party’s disclosure to the Receiving Party, is obtained by the Receiving Party from a third Party which is lawfully in possession of such information and not subject to a known contractual or fiduciary relationship
to the Disclosing Party with respect thereto. 

  

	7.7.	Upon the termination of this Agreement, the Receiving Party shall, if so requested by the Disclosing Party, promptly return to the Disclosing Party the originals and all copies of any Proprietary Information then in the
Receiving Party’s possession. Notwithstanding the foregoing, Receiving Party may retain one copy of such Proprietary Information in its archives solely for the purpose of demonstrating compliance with the terms hereof. 

 

	7.8.	The Parties understand that any breach by the Receiving Party of any of the obligations set forth in this Section 7 might cause irreparable harm to the Disclosing Party for which compensation by monetary damages
would be inadequate. Therefore, in the event of any breach or threatened breach of the provisions of this Section 7 by the Receiving Party, the Disclosing Party shall have the right to seek an injunction or other appropriate equitable relief,
without the necessity of posting a bond or other form of financial assurance and in addition to any other remedies that may be available. 

  

	8.	QUALITY OF NALTREXONE HYDROCHLORIDE; REGULATORY MATTERS; REPRESENTATIONS AND
WARRANTIES 

  

	8.1.	At all times during [*...***...], MALLINCKRODT shall ensure that its relevant facilities shall remain in material compliance with, and the Naltrexone
Hydrochloride shall be manufactured in material compliance with, (i) all applicable laws, rules and regulations, including but not limited to, the provisions of the Federal Food, Drug, and Cosmetic Act, as amended from time to time (the
“Act”), (ii) current Good Manufacturing Practices as defined by the Act and the rules, regulations and practice standards issued and administered by the FDA and the equivalent regulations promulgated by any foreign regulatory agency
with an equivalent function and appropriate jurisdiction, any of the foregoing as they relate to the manufacture of bulk active pharmaceutical ingredients (“cGMP”) and (iii) the FDA’s regulations for drug establishment
registration. 

  
 * ***Confidential Treatment Requested 
 Confidential

 CSK/Orexigen –Mallinckrodt Amended & Restated Naltrexone Hydrochloride Supply Agreement 

  
 10 

 MALLINCKRODT shall keep records of the manufacture, testing, and shipping of Naltrexone
Hydrochloride, and retain samples of the Naltrexone Hydrochloride, and components used in its manufacture, as necessary to comply with all applicable laws, including without limitation any manufacturing regulatory requirements applicable to
MALLINCKRODT, the manufacturing site, the Naltrexone Hydrochloride, and components used in its manufacture, as well as to assist with resolving complaints and other similar investigations relating to such Naltrexone Hydrochloride and/or any Finished
Product. MALLINCKRODT shall retain copies of the records and sample for a period ending not earlier than one year following the date of Naltrexone Hydrochloride expiry, or for such longer period as may be required by applicable law, at which time
MALLINCKRODT shall contact OREXIGEN concerning the delivery of such records. At OREXIGEN’s request, MALLINCKRODT shall, [*...***...], return such records to OREXIGEN. 

 

	8.2.	No Naltrexone Hydrochloride constituting a part of any shipment to OREXIGEN shall at the time of any such shipment be adulterated within the meaning of the Act, or the rules and regulations promulgated thereunder, as
such law, rule or regulation is in effect at the time of any such shipment. 

  

	8.3.	All Naltrexone Hydrochloride supplied to OREXIGEN hereunder (i) shall at the time of delivery meet the Specifications and (ii) will have expiration dating of not less than [...***...] in accordance with
this Agreement. 

  

	8.4.	All necessary licenses, permits or approvals required by applicable laws in connection with the manufacture, storage and shipment of Naltrexone Hydrochloride hereunder, including without limitation permits related to
manufacturing facilities, shall be maintained during the term hereof. 

  

	8.5.	In the event of any inquiries directed to MALLINCKRODT by the FDA or any other Regulatory Agency that could have a material adverse impact on the supply of Naltrexone Hydrochloride for OREXIGEN under this Agreement,
prior to responding to any such inquiry MALLINCKRODT shall notify OREXIGEN, and the Parties will discuss an appropriate response. [...***...]. 

  

	8.6.	 [...***...] any pending or threatened claim by a third party, or any reasonable basis for any such claim, that the Naltrexone Hydrochloride
supplied hereunder 

  
 * ***Confidential Treatment Requested 
 Confidential

 CSK/Orexigen –Mallinckrodt Amended & Restated Naltrexone Hydrochloride Supply Agreement 

  
 11 

	 	
or MALLINCKRODT’s process for manufacturing the Naltrexone Hydrochloride supplied hereunder would infringe, misappropriate or violate any patent, trade secret or other intellectual property
right in effect. 

  

	8.7.	[*...***...], the Finished Product will not infringe, misappropriate or violate any third party patent, trade secret or other intellectual property right in
effect during the Term in the United States and in any of the jurisdictions set forth in Schedule B (provided, that OREXIGEN’s representation does not extend to any infringement, misappropriation or violation that arises out of or
relates to Naltrexone Hydrochloride or MALLINCKRODT’s process for manufacturing Naltrexone Hydrochloride). 

  

	8.8.	Each Party represents and warrants that all corporate action on its part and on the part of each of its officers and directors necessary for the authorization, execution and delivery of this Agreement has been taken,
that it has the full right and authority to enter into this Agreement and perform its obligations hereunder, that it is not aware of any obligations owed to third parties that would conflict with its ability to perform its obligations hereunder, and
that this Agreement represents the binding obligation of each Party enforceable against it in accordance with its terms. 

  

	8.9.	If requested in writing by OREXIGEN, MALLINCKRODT shall permit OREXIGEN or its authorized representatives, during normal business hours, and, except for for-cause audits or inspections, [...***...], to inspect
MALLINCKRODT’s facilities and records and be given access to MALLINCKRODT’s personnel ([...***...]), to the extent OREXIGEN deems [...***...] to enable OREXIGEN to verify compliance by MALLINCKRODT with its obligations under
this Agreement and to verify MALLINCKRODT’s compliance with any applicable laws. Any such inspection shall be carried out in a manner reasonably contemplated to avoid disruption of MALLINCKRODT’s normal conduct of business and in
accordance with all applicable safety and site regulations of MALLINCKRODT. 

  

	8.10.	In the event that MALLINCKRODT receives any complaint, claims or adverse reaction reports regarding Naltrexone Hydrochloride that is manufactured for OREXIGEN pursuant to this Agreement, including notices from the FDA
regarding any alleged regulatory noncompliance of Naltrexone Hydrochloride (including any FDA Form 483s or warning letters), which would reasonably be expected to delay any shipment or otherwise adversely affect either MALLINCKRODT’s
performance hereunder or the quality of the Naltrexone Hydrochloride supplied hereunder, MALLINCKRODT shall (a) [...***...], provide to OREXIGEN material information concerning the complaint, claim, report or notice and such additional
information as OREXIGEN may reasonably request and (b) (i) conduct, [...***...], an investigation to determine the cause of such noncompliance, and (ii) assist OREXIGEN in investigating any such noncompliance at OREXIGEN’s
request. MALLINCKRODT shall comply, at a minimum, with FDA requirements with respect to any such complaints, claims or adverse reaction reports. 

  
 * ***Confidential Treatment Requested 
 Confidential

 CSK/Orexigen –Mallinckrodt Amended & Restated Naltrexone Hydrochloride Supply Agreement 

  
 12 

	8.11.	OREXIGEN and MALLINCKRODT represent and warrant that each of them shall comply with all relevant laws, rules and regulations in the performance of any obligations hereunder. 

 

	8.12.	MALLINCKRODT covenants that it will not, in the performance of its obligations under this Agreement, knowingly use the services of any person debarred or suspended under 21 U.S.C. §35(a) or (b). MALLINCKRODT
represents that it does not currently have, and covenants that it will not knowingly hire, as an officer or an employee, any person who has been convicted of a felony under the laws of the United States for conduct relating to the regulation of any
drug product under the Act. 

  

	8.13.	MALLINCKRODT shall promptly notify OREXIGEN of any information of the following kind about Naltrexone Hydrochloride provided to OREXIGEN: 

 

	 	8.13.1.	[*...***...] 

  

	 	8.13.2.	[...***...] Hydrochloride, including stability parameters. 

  

	8.14.	The Parties have previously entered or shall enter into a Quality Agreement within [...***...] after the date of execution of this Agreement (the “Quality Agreement”). In the event there is any conflict
or inconsistency in the terms and provisions of this Agreement and the Quality Agreement, the terms and provisions of this Agreement shall control and prevail in every case. 

 

	8.15.	MALLINCKRODT represents and warrants that it will comply in all material respects with all applicable laws throughout the term of this Agreement, including providing all required written certifications, representations,
and disclosures. Specifically, MALLINCKRODT represents and warrants that it will comply in all material respects with applicable requirements of the following Federal Acquisition Regulation (“FAR”) clauses, which are hereby incorporated by
reference and made a part of this Agreement as if fully set forth herein: (i) FAR 52.203-13, Contractor Code of Business Ethics and Conduct (Apr. 2010); (ii) FAR 52.219-8, Utilization of Small Business Concerns (Dec. 2010) (15 U.S.C.
§ 637(d)(2) and (3)); (iii) FAR 52.222-26, Equal Opportunity (Mar. 2007) (Executive Order 11246); (iv) FAR 52.222-35, Equal Opportunity for Veterans (Sep. 2010) (38 U.S.C. § 4212); (v) FAR 52.222-36, Affirmative Action for
Workers with Disabilities (Oct. 2010) (29 U.S.C. § 793); (vi) FAR 52.222-40, Notification of Employee Rights Under the National Labor Relations Act (Dec. 2010) (E.O. 13496); (vii) FAR 52.222-50 Combating Trafficking in Persons (Feb.
2009) (22 U.S.C. 7104(g)) and (viii) FAR 52.247-64, Preference for Privately Owned U.S.-Flag Commercial Vessels (Feb 2006). BY ACCEPTANCE OF THIS AGREEMENT, MALLINCKRODT HEREBY CERTIFIES THAT NEITHER MALLINCKRODT NOR ANY OF MALLINCKRODT’S
PRINCIPALS IS PRESENTLY DEBARRED, SUSPENDED, PROPOSED FOR DEBARMENT, DECLARED INELIGIBLE FOR OR VOLUNTARILY EXCLUDED FROM THE AWARD OF CONTRACTS BY ANY U.S. FEDERAL AGENCY. 

  
 * ***Confidential Treatment Requested 
 Confidential

 CSK/Orexigen –Mallinckrodt Amended & Restated Naltrexone Hydrochloride Supply Agreement 

  
 13 

	8.16.	EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NO PARTY MAKES ANY WARRANTIES, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, AND EACH PARTY SPECIFICALLY DISCLAIMS ANY AND ALL IMPLIED WARRANTIES OF ANY KIND, INCLUDING
(WITHOUT LIMITATION) ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 

  

	9.	INDEMNIFICATION 

  

	9.1.	Except to the extent resulting from any claim subject to MALLINCKRODT’s indemnification obligations under Section 9.2, OREXIGEN hereby agrees to and shall defend, indemnify, and hold harmless MALLINCKRODT, its
Affiliates and each of their respective employees, officers, directors and agents (the “MALLINCKRODT Indemnitees”), from, against and in respect of any and all losses, judgments, damages, liabilities, suits, actions, expenses (including
reasonable attorney’s fees) and proceedings arising from any claims of any third party to the extent resulting from: 

  

	 	9.1.1.	any allegation of misrepresentation, breach of warranty, or the non-fulfillment of any obligation, covenant or duty on the part of OREXIGEN under this Agreement, 

 

	 	9.1.2.	any claim, complaint, suit, proceeding or cause of action against any of the MALLINCKRODT Indemnitees alleging physical injury or death, brought by or on behalf of an injured party, or loss of service or consortium or a
similar such claim, complaint, suit, proceeding or cause of action brought by a spouse, relative or companion of an injured party due to such physical injury or death, to the extent arising out of OREXIGEN’s or OREXIGEN’s [*...***...] of any [...***...] (except to the extent that MALLINCKRODT has breached its obligations under [...***...] with respect to such Naltrexone Hydrochloride), and whether used
alone or in combination with any other material, 

  

	 	9.1.3.	any [...***...] willful misconduct of OREXIGEN, its employees, officers and directors in performing this Agreement, and 

  

	 	9.1.4.	any claim of [...***...]. 

  

	9.2.	 Except to the extent resulting from any claim subject to OREXIGEN’s indemnification obligations under Section 9.1, MALLINCKRODT hereby
agrees to and shall defend, indemnify, and hold harmless OREXIGEN, its Affiliates and each of their respective employees, officers, directors and agents (the “OREXIGEN Indemnitees”), from, against

  
 * ***Confidential Treatment Requested 
 Confidential

 CSK/Orexigen –Mallinckrodt Amended & Restated Naltrexone Hydrochloride Supply Agreement 

  
 14 

	 	
and in respect of any and all losses, judgments, damages, liabilities, suits, actions, expenses (including reasonable attorney’s fees) and proceedings arising from any claims of any third
party to the extent resulting from: 

  

	 	9.2.1.	any allegation of misrepresentation, breach of warranty, or the nonfulfillment of any obligation, covenant, or duty on the part of MALLINCKRODT under this Agreement, 

 

	 	9.2.2.	any claim, complaint, suit, proceeding or cause of action against any of the OREXIGEN Indemnitees alleging physical injury or death, brought by or on behalf of an injured party, or loss of service or consortium or a
similar such claim, complaint, suit, proceeding or cause of action brought by a spouse, relative or companion of an injured party due to such physical injury or death, to the extent arising out of MALLINCKRODT’s breach of its obligations under
[*...***...] with respect to such Naltrexone Hydrochloride, 

  

	 	9.2.3.	any [...***...] willful misconduct of MALLINCKRODT or its employees, officers or directors in performing this Agreement, and 

  

	 	9.2.4.	any claim of [...***...]. 

  

	9.3.	The foregoing indemnification obligations are subject to the following: 

  

	 	9.3.1.	in the event a third party claim forms the basis for indemnification, the indemnifying Party must be notified by or on behalf of the indemnified Party in writing promptly after a claim is made, a suit is filed or an
action or investigation is initiated (each, a “Proceeding”) against the indemnified Party, unless such delay does not materially prejudice the indemnifying Party, 

 

	 	9.3.2.	subject to the provisions set forth below in this Section 9.3, the indemnifying Party shall be permitted to defend, control, conduct and prosecute, in the indemnifying Party’s sole discretion and by counsel of
the indemnifying Party’s choosing, the defense of such Proceeding brought against the indemnified Party, 

  

	 	9.3.3.	 the indemnifying Party shall have the right in its sole discretion to settle, compromise or otherwise terminate the Proceeding solely upon the payment
of money, provided, that there is no finding or admission of any violation by any indemnified Party of (i) any law, rule or regulation or (ii) the rights of any person, and provided further, that no such settlement shall prohibit any
indemnified Party from importing the Naltrexone Hydrochloride into the United States and or making, using or selling products in the United States and made from such Naltrexone Hydrochloride, and provided further, that no such settlement by the
indemnifying Party shall be entered into without the prior consent of the indemnified Party if such settlement contains any terms or conditions that might in 

  
 * ***Confidential Treatment Requested 
 Confidential

 CSK/Orexigen –Mallinckrodt Amended & Restated Naltrexone Hydrochloride Supply Agreement 

  
 15 

	 	
any way limit, restrict or prevent the indemnified Party from carrying on any of its business activities, 

  

	 	9.3.4.	the indemnified Party shall refrain from settling (or endeavoring to settle, or entering into settlement negotiations with respect to) any such Proceeding without the indemnifying Party’s prior written consent,

  

	 	9.3.5.	except as may otherwise be required by law, the indemnified Party shall not compromise the position of the indemnifying Party by admission, statements, disclosure or conduct (collectively, “Disclosure”) in a
way that could reasonably prejudice the defense, control, conduct or prosecution of said cause of action (it being understood that no indemnified Party shall be deemed to have violated this provision so long as such Party has acted in good faith to
fulfill its obligations under this provision), and 

  

	 	9.3.6.	the indemnified Party shall cooperate with the indemnifying Party in the defense, conduct, prosecution or termination of the Proceeding, including the furnishing of information and the assistance from employees of the
indemnified Party, at the indemnifying Party’s reasonable request and expense. 

 Notwithstanding anything to the contrary
in this Section 9.3, [*...***...], (i) [...***...] defend, control, conduct and prosecute, by counsel of [...***...], the defense of such Proceeding,
(ii) [...***...] shall refrain from settling (or endeavoring to settle, or entering into settlement negotiations with respect to) any such Proceeding [...***...], (iii) except as may otherwise be required by law,
[...***...] shall compromise the position of [...***...] by Disclosure in a way that could reasonably prejudice the defense, control, conduct or prosecution of said cause of action (it being understood that [...***...] shall be
deemed to have violated this provision so long as [...***...] has acted in good faith to fulfill its obligations under this provision), and (iv) [...***...] shall cooperate with [...***...] in the defense, conduct, prosecution
or termination of the Proceeding, including the furnishing of information and the assistance from employees of [...***...], at [...***...] reasonable request and expense. 

 

	9.4.	With respect to Section 9.3 above, the indemnified Party will (if legally possible under the applicable circumstances) provide the indemnifying Party with prompt written notice in advance of any such Disclosure
being made to permit the indemnifying Party to seek an appropriate protective order, restriction on response or withdrawal of the request for Disclosure. If, however, any such request for relief by the indemnifying Party is denied or is otherwise
unavailable, the relevant indemnified Party may make the Disclosure without any liability to the indemnifying Party. 

  
 * ***Confidential Treatment Requested 
 Confidential

 CSK/Orexigen –Mallinckrodt Amended & Restated Naltrexone Hydrochloride Supply Agreement 

  
 16 

	9.5.	The indemnified Party may, at its option and expense, participate in the indemnifying Party’s defense with counsel of its own choosing, and if the indemnified Party so participates, the Parties shall cooperate with
one another in such defense in a commercially reasonable fashion. Notwithstanding any provision in this Agreement to the contrary, OREXIGEN shall at all times have the right to assume direction and control of the defense of any claim for which it
has agreed to indemnify MALLINCKRODT hereunder alleging infringement, misappropriation or violation of any patent, trade secret or other intellectual property right of any third party, provided that OREXIGEN will provide MALLINCKRODT, if appropriate
under the applicable circumstances, with a reasonable opportunity to review and consult from time to time concerning the strategy and action plan, and in such event MALLINCKRODT shall cooperate and assist as requested in the defense of such claim.

  

	9.6.	Notwithstanding anything to the contrary in this Section 9, each Party may, and expressly reserves the right to, seek judicial relief from any court of competent jurisdiction in order to obtain an injunction or
other equitable relief for the purpose of enforcing its rights under this Section 9. 

  

	9.7.	NOTWITHSTANDING ANY OTHER PROVISION HEREOF, IN NO EVENT SHALL ANY OF THE PARTIES HERETO BE RESPONSIBLE OR LIABLE TO THE OTHER UNDER ANY PROVISION OF THIS AGREEMENT OR UNDER ANY THEORY OF NEGLIGENCE, STRICT LIABILITY OR
OTHER LEGAL OR EQUITABLE THEORY, FOR ANY CONSEQUENTIAL, INDIRECT, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES (INCLUDING, WITHOUT LIMITATION, DAMAGES FOR LOST PROFITS OR BUSINESS INTERRUPTION), WHETHER OR NOT A PARTY HAS BEEN ADVISED OF THE POSSIBILITY
OF SUCH DAMAGES AND WHETHER OR NOT SUCH DAMAGES ARE REASONABLY FORESEEABLE; PROVIDED THAT, FOR CLARITY, THE FOREGOING LIMITATION OF LIABILITY SHALL NOT APPLY TO THE OBLIGATION OF OREXIGEN TO INDEMNIFY MALLINCKRODT PURSUANT TO SECTION [*...***...] OR TO THE OBLIGATION OF MALLINCKRODT TO INDEMNIFY OREXIGEN PURSUANT TO SECTION [...***...]. NOTHING IN THIS SECTION IS INTENDED TO LIMIT THE OBLIGATIONS OF EITHER PARTY UNDER
SECTION 7 ABOVE. 

  

	10.	ADVERSE EVENT REPORTING; COSTS AND EXPENSES OF RECALL 

 

	10.1.	 OREXIGEN shall have sole control and responsibility for reporting all adverse events associated with the use of Finished Products in humans, whether
expected or unexpected and whether or not considered drug related, including the following: (i) an adverse event occurring in the course of the use of a drug product in professional practice, (ii) an adverse event occurring from drug
overdose whether accidental or intentional, (iii) an adverse event occurring from drug abuse, (iv) an adverse event occurring from drug withdrawal, and (v) any failure of expected pharmacological action with respect to the Finished
Products (collectively, “Adverse Events”). OREXIGEN shall also have sole control and responsibility for responding to all Finished Product quality complaints and medical and technical inquiries, whether from lay persons, health care
professionals and or Regulatory Agencies. Notwithstanding the foregoing, to the extent MALLINCKRODT has an 

  
 * ***Confidential Treatment Requested 
 Confidential

 CSK/Orexigen –Mallinckrodt Amended & Restated Naltrexone Hydrochloride Supply Agreement 

  
 17 

	 	
obligation to report any Adverse Events to any Regulatory Agencies it may do so provided it first provides written notice to OREXIGEN thereof and a copy of such report. In the event MALLINCKRODT
[*...***...], it shall notify OREXIGEN within [...***...] thereof. 

  

	10.2.	OREXIGEN shall have sole control and responsibility for conducting or initiating (as appropriate) any product recall, product withdrawal, governmental seizure or field correction with respect to any Finished Products
(“Recalls”). If OREXIGEN reasonably decides to or is required to initiate a product Recall with respect to Finished Products containing any Naltrexone Hydrochloride supplied hereunder which action is due, in whole or in part, to
[...***...], OREXIGEN will notify MALLINCKRODT promptly of the details regarding such action, including providing copies of all relevant documentation concerning such action. MALLINCKRODT will assist OREXIGEN in investigating any such
situation and all regulatory contacts that are made and all activities concerning such Recall will be the [...***...] responsibility of [...***...]. If any such Recall occurs due solely to [...***...], then [...***...] shall
bear the [...***...] cost and expense of any such Recall. If, on the other hand, any such Recall occurs due solely to [...***...], then [...***...] shall bear the [...***...] cost and expense of any such Recall and all
regulatory contacts that are made will be the sole responsibility of [...***...]. If both [...***...] contribute to the cause of any Recall, the cost and expenses thereof [...***...], and all activities concerning such Recall will
be the [...***...] responsibility of [...***...]. 

  
 * ***Confidential Treatment Requested 
 Confidential

 CSK/Orexigen –Mallinckrodt Amended & Restated Naltrexone Hydrochloride Supply Agreement 

  
 18 

	11.	TERM AND TERMINATION 

  

	11.1.	This Agreement shall commence on the Effective Date (i.e., January 1, 2015) and shall continue in effect until December 31, 2018 (the “Term”), unless earlier terminated. This Agreement may only be
extended with the express written agreement of both MALLINCKRODT and OREXIGEN. 

  

	11.2.	This Agreement may be terminated by (i) OREXIGEN upon ninety (90) days written notice to MALLINCKRODT of a failure by MALLINCKRODT to perform or observe any material covenant, condition or agreement to be
performed or observed by it under this Agreement, unless such breach has been cured within the ninety (90) day notice period, and (ii) MALLINCKRODT upon ninety (90) days written notice to OREXIGEN of a failure by OREXIGEN to perform
or observe any material covenant, condition or agreement to be performed or observed by it under this Agreement, unless such breach has been cured within the ninety (90) day notice period; provided, however, that with respect to a failure to
timely supply ordered quantities of Naltrexone Hydrochloride under this Agreement, MALLINCKRODT shall have the right to cure such breach no more than once during any calendar year unless otherwise agreed by OREXIGEN in writing; and provided further,
that if the breach by OREXIGEN is a failure to pay an invoice when due, the notice and cure period shall be thirty (30) days. 

  

	11.3.	OREXIGEN may terminate this Agreement effective immediately upon written notice to MALLINCKRODT in the event that (a) MALLINCKRODT dissolves, is declared insolvent or bankrupt by a court of competent jurisdiction,
(b) a voluntary or involuntary (if not dismissed within sixty (60) days) petition of bankruptcy is filed in any court of competent jurisdiction by or against MALLINCKRODT, or (c) this Agreement is assigned by MALLINCKRODT for the
benefit of creditors. MALLINCKRODT may terminate this Agreement effective immediately upon written notice to OREXIGEN in the event that (a) OREXIGEN dissolves, is declared insolvent or bankrupt by a court of competent jurisdiction, (b) a
voluntary or involuntary (if not dismissed within sixty (60) days) petition of bankruptcy is filed in any court of competent jurisdiction by or against OREXIGEN, or (c) this Agreement is assigned by OREXIGEN for the benefit of creditors.

  

	11.4.	OREXIGEN may terminate this Agreement effective upon sixty (60) days written notice to MALLINCKRODT in the event that (a) any Regulatory Agency takes any action, or raises any objection, that completely
prevents OREXIGEN from importing, exporting, purchasing or selling either the Naltrexone Hydrochloride or the Finished Product, (b) the Finished Product fails during clinical trials and OREXIGEN withdraws its NDA, or (c) OREXIGEN
determines, in its sole discretion, to no longer pursue the development and/or commercialization of a Finished Product which contains Naltrexone Hydrochloride, provided that, any such notice shall clearly state the reasons for termination.

  

	11.5.	 In the event of termination of this Agreement by either Party pursuant to any of Sections 11.2, 11.3 or 11.4 (except for any termination hereof by
OREXIGEN pursuant to Section 11.2), OREXIGEN agrees to pay for previously placed orders of Naltrexone Hydrochloride but not yet delivered to OREXIGEN, provided that MALLINCKRODT shall use reasonable commercial efforts to mitigate the amount of
such payments by 

  
 Confidential 

CSK/Orexigen –Mallinckrodt Amended & Restated Naltrexone Hydrochloride Supply Agreement 

  
 19 

	 	
OREXIGEN, including, but not limited to, selling such Naltrexone Hydrochloride to other customers, and provided further that MALLINCKRODT shall deliver Naltrexone Hydrochloride pursuant to such
orders in accordance with this Agreement. 

  

	11.6.	The provisions of this Section 11 as to termination shall not limit or restrict the rights of any Party to seek remedies or take measures that may be otherwise available to it at law or equity in connection with
the enforcement and performance of obligations under this Agreement. 

  

	12.	NOTICES 

 Any and all notices required to be given under this Agreement will be in writing
and effective upon receipt, sent by facsimile transmission, mailed postage prepaid by first-class certified or registered mail, or sent by express courier service, at the respective addresses, as follows: 

If to OREXIGEN: 
 Orexigen Therapeutics,
Inc. 
 3344 N. Torrey Pines Court, Suite 200 

La Jolla, CA 92037 
 Attention:
VP, Technical Operations 
 Telephone Number: (858) 875-8600 

Facsimile Number: (858) 875-8650 
 With a
copy to (which shall not by itself constitute notice): 
 Orexigen Therapeutics, Inc. 

3344 N. Torrey Pines Court, Suite 200 

La Jolla, CA 92037 
 Attention:
General Counsel 
 Telephone Number: (858) 875-8600 

Facsimile Number: (858) 875-8650 
 If to
MALLINCKRODT: 
 Mallinckrodt LLC 

675 McDonnell Blvd. 
 Hazelwood,
MO 63042 
 Attention: Senior Director Global API 

Telephone Number: (314) 654-5719 

Facsimile Number: (314) 654-6580 

  
 Confidential 

CSK/Orexigen –Mallinckrodt Amended & Restated Naltrexone Hydrochloride Supply Agreement 

  
 20 

 With a copy to (which shall not by itself constitute notice): 

Mallinckrodt LLC 
 675 McDonnell
Blvd. 
 Hazelwood, MO 63042 

Attention: C. Stephen Kriegh, Vice President – Legal 

Telephone Number: (314) 654-6040 

Facsimile Number: (314) 654-7181 
  

	13.	MISCELLANEOUS 

  

	13.1.	Force Majeure. In the event that any Party hereto is prevented from complying, either in whole or in part, with any of the terms or provisions of this Agreement by reason of fire, flood, storm, strike or lockout,
riot, war, rebellion, lack or failure of transportation facilities, court order, Acts of God or any other event or circumstance beyond a Party’s reasonable control, then, upon written notice by the Party whose performance is so affected to the
other, the requirements of this Agreement so affected (to the extent affected) shall be suspended during the period of, and only to the extent of, such disability. Said Party shall be excused by reason of said force majeure only so long as it is
exercising [*...***...] to overcome any event of force majeure. Notwithstanding the foregoing, if a force majeure event prevents a Party’s performance under this Agreement for more than
one hundred twenty (120) continuous days, the other Party may terminate this Agreement upon written notice to the non-performing Party. 

  

	13.2.	Assurances. Each Party to this Agreement shall execute, acknowledge and deliver such further instruments and documents, and do all such other acts and things as may be required by law or as may be necessary or
advisable to carry out the intents and purposes of this Agreement. The Parties will cooperate with each other and offer reasonable assistance in carrying out their respective responsibilities under this Agreement. 

 

	13.3.	 Dispute Resolution. Any dispute, controversy or claim arising under, out of or in connection with this Agreement, including any subsequent
amendments, or the validity, enforceability, construction, performance or breach thereof (“Dispute”), may, if and only if both Parties expressly agree in any circumstance, be finally settled under the Rules for Commercial Dispute
Resolution Procedures (“Rules”) of the American Arbitration Association (“AAA”) then in force on the date of commencement of the arbitration by three (3) arbitrators appointed in accordance with those Rules, provided that
the arbitrators appointed have at least ten (10) years arbitration experience in the pharmaceutical industry; provided, however, if the Parties mutually agree, such arbitration may be conducted by a single mutually agreeable arbitrator. The
award rendered shall be final and binding on the Parties. Judgment upon the award may be entered in any court having jurisdiction. The Parties agree that they will not request, and the arbitrators shall have no authority to award, punitive or
exemplary damages against either Party. The costs of any arbitration, including administrative fees and fees of the arbitrators, shall be shared equally by the Parties and each Party shall bear the cost of its own attorneys’ and expert fees,
provided that the arbitrator(s) shall have the discretion, to be exercised in accordance with applicable law, to allocate among the Parties the arbitrators’ fees and litigation costs, and the arbitrator(s)

  
 * ***Confidential Treatment Requested 
 Confidential

 CSK/Orexigen –Mallinckrodt Amended & Restated Naltrexone Hydrochloride Supply Agreement 

  
 21 

	 	
shall also have authority to shift any prevailing Party’s attorney’s fees to any non-prevailing Party. 

 

	13.4.	Governing Law. This Agreement shall be governed by and construed under the laws of the State of New York, excluding its conflicts of law provisions that might apply the law of another jurisdiction.

  

	13.5.	Severability. If any provision of this Agreement shall be held to be invalid, illegal or unenforceable, the validity, legality, or enforceability of the remaining provisions hereof shall not in any way be
affected or impaired thereby unless the essential purpose(s) of this Agreement cannot be achieved by either or both of the Parties. In the event any provision shall be held invalid, illegal or unenforceable the Parties shall use best efforts to
substitute a valid, legal and enforceable provision which insofar as practical implements the purposes hereof. 

  

	13.6.	No Assignment. No Party shall assign its rights and/or obligations under this Agreement without the prior written consent of the other Parties hereto, except that (a) OREXIGEN may assign this Agreement in
connection with the transfer, license or sale of all or substantially all of its assets or business to which the subject matter of this Agreement relates or in connection with any merger, consolidation or reorganization, without MALLINCKRODT’s
prior written consent, and (b) MALLINCKRODT may assign this Agreement in connection with the transfer, license or sale of all or substantially all of its assets or business to which the subject matter of this Agreement relates or in connection
with any merger, consolidation or reorganization without OREXIGEN’s prior written consent. 

  

	13.7.	Waiver. No delay, waiver, omission or forbearance on the part of any Party to exercise any right, option, duty or power arising out of any breach or default by any other Party of any of the terms, provisions or
covenants hereof, will constitute a waiver by such Party of its rights to enforce any such right, option, duties or power as against the other Party hereto, or its rights as to any subsequent breach or default by the other Party. 

 

	13.8.	Survival. Upon termination or expiration of this Agreement, the obligations of the Parties which by their nature should survive and the obligations under Sections 7-13 of this Agreement and under any existing
confidentiality agreements between the Parties shall survive. 

  

	13.9.	 Entire Agreement. This Agreement and the Schedules and Appendices attached hereto, the confidentiality agreements referenced in
Section 13.8 and the Quality Agreement (when executed) constitute the full understanding and entire agreement between the Parties with respect to the subject matter hereof and supersede any and all prior oral or written understandings and
agreements with respect to the subject matter hereof. No terms, conditions, understandings or agreements purporting to modify, amend, waive or terminate this Agreement, or any provision hereof, shall be binding except by the execution of a writing
specified to be an explicit amendment to this Agreement duly executed by the authorized signatories of the Parties hereto. No modification, waiver, termination, 

  
 Confidential 

CSK/Orexigen –Mallinckrodt Amended & Restated Naltrexone Hydrochloride Supply Agreement 

  
 22 

	 	
rescission, discharge or cancellation of any right or claim under this Agreement shall affect the right of any Party to enforce any other claim or right hereunder. 

 

	13.10.	Binding Agreement. Subject to Section 13.6, this Agreement shall be binding upon the Parties and their respective successors and permitted assigns and shall insure to the benefit of the Parties and their
respective successors and permitted assigns. 

  

	13.11.	Headings. The headings used in this Agreement are for convenience of reference only and are not a part of the text hereof. 

  

	13.12.	Counterparts; Electronic Delivery. This Agreement may be executed in counterparts, each of which shall constitute an original and all of which shall together constitute a single agreement. A facsimile, PDF or any
other type of copy of an executed version of this Agreement signed by a Party is binding upon the signing party to the same extent as the original of the signed Agreement, and may be delivered electronically. 

[Signature Page Follows] 

  
 Confidential 

CSK/Orexigen –Mallinckrodt Amended & Restated Naltrexone Hydrochloride Supply Agreement 

  
 23 

 IN WITNESS WHEREOF, the Parties hereby agree to the terms and conditions of this Agreement. 

 

									
	OREXIGEN THERAPEUTICS, INC.	 		 	MALLINCKRODT LLC
					
	By:	 	 /s/ Michael A. Narachi
	 		 	By:	 	 /s/ Walt Kaczmarek

	Name:	 	Michael A. Narachi	 		 	Name:	 	Walt Kaczmarek
	Title:	 	President & Chief Executive Officer	 		 	Title:	 	President - Multi-Source Pharmaceuticals
					
	Date:	 	 May 26, 2015
	 		 	Date:	 	 May 12, 2015

					
	By:	 	 /s/ Joseph P. Hagan
	 		 		 	
	Name:	 	Joseph P. Hagan	 		 		 	
	Title:	 	EVP, Chief Business and Financial Officer	 		 		 	
	Date:	 	 May 26, 2015
	 		 		 	
					
	By:	 	 /s/ Philip Roberts
	 		 		 	
	Name:	 	Philip Roberts	 		 		 	
	Title:	 	VP, Technical Operations	 		 		 	
	Date:	 	 May 26, 2015
	 		 		 	

  
 Confidential 

CSK/Orexigen –Mallinckrodt Amended & Restated Naltrexone Hydrochloride Supply Agreement 

  
 24 

 LIST OF DEFINED TERMS 

 

			
	 DEFINED TERM
	  	 SECTION

		
	 AAA
	  	13.3
	 Act
	  	8.1
	 Adverse Events
	  	10.1
	 Affiliate
	  	1.1
	 Agreement
	  	Preamble
	 cGMP
	  	8.1
	 Defective Product
	  	6.1
	 Direct Manufacturing Cost
	  	2.2
	 Disclosing Party
	  	7.1
	 Disclosure
	  	9.3
	 Dispute
	  	13.3
	 DMF
	  	2.1
	 DMF Equivalent
	  	2.1
	 Effective Date
	  	Preamble
	 FAR
	  	8.15
	 FDA
	  	2.2
	 Finished Product
	  	2.2
	 MALLINCKRODT
	  	Preamble
	 MALLINCKRODT Indemnitees
	  	9.1
	 OREXIGEN
	  	Preamble
	 OREXIGEN Indemnitees
	  	9.2
	 Orexigen Licensee
	  	2.4
	 Party
	  	Preamble
	 Parties
	  	Preamble
	 Price
	  	5.1
	 Proceeding
	  	9.3
	 Proprietary Information
	  	7.1
	 Purchase Order
	  	1.2
	 Quality Agreement
	  	8.14
	 Recalls
	  	10.2
	 Receiving Party
	  	7.1
	 Regulatory Agency
	  	2.2
	 Regulatory Price Change
	  	5.2
	 Rejection Notice
	  	6.1
	 Representatives
	  	7.3
	 Response Notice
	  	6.2
	 Rolling Forecast
	  	3.2
	 Rules
	  	13.3
	 Specifications
	  	2.1
	 Term
	  	11.1

 SCHEDULE A 

SPECIFICATIONS 
 [*...***...] 

  
 * ***Confidential Treatment Requested 

 SCHEDULE B 

CERTAIN AGREED JURISDICTIONS 
 [*...***...] 

  
 * ***Confidential Treatment Requested 

 SCHEDULE C 

PRICING AND SHIPPING TERMS 
 Freight
Terms: All Naltrexone Hydrochloride shall be delivered [*...***...]. 
 Shipping
Method: Land within North America, otherwise Air Freight 
 Tiered Pricing: 
  

	 	(1)	[...***...] 

  

			
	[...***...]	  	[...***...]
	[...***...]	  	[...***...]
	[...***...]	  	[...***...]
	[...***...]	  	[...***...]

 [...***...] 

  
 * ***Confidential Treatment Requested 

 SCHEDULE D 

INITIAL FORECAST (in kilograms) 
  

																									
		 	[*...***...]	 		 		 		 		 		 		 		 	
		 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
					
		 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]

  
 * ***Confidential Treatment RequestedEX-10.3

 Exhibit 10.3 

***Text Omitted and Filed Separately 

with the Securities and Exchange Commission. 

Confidential Treatment Requested 

Under 17 C.F.R. Sections 200.80(b)(4) 

and 240.24b-2. 
 OREXIGEN
THERAPEUTICS, INC. 
 CONSULTING AGREEMENT 

THIS CONSULTING AGREEMENT (this “Agreement”) is
effective as of June 26, 2015 (the “Effective Date”), by and between OREXIGEN THERAPEUTICS, INC. (the “Company”) and HEATHER
D. TURNER (the “Consultant”). 
 1. SERVICES. 

a. The Company retains the Consultant and the Consultant agrees to render the consulting services (“Services”)
pursuant to the terms and conditions described in the statement of work (“Statement of Work” or “SOW”) attached to this Agreement as Exhibit A. 

b. The Consultant will not perform any Services for the Company except as authorized or requested by the Company. The Consultant agrees to
complete the Services in a satisfactory manner and in accordance with generally accepted professional standards prevailing at the time the Services are performed. 

c. Within ten (10) days after the Effective Date, the Consultant shall provide a complete and accurate form W-9 to the Company. 

2. TERM AND TERMINATION. 

a. This Agreement is effective as of the Effective Date, and will terminate on March 31, 2016 (the “Termination
Date”), unless extended by mutual consent of the Consultant and the Company. Notwithstanding the foregoing, the Company can terminate this Agreement (and any SOW) at any time prior to the Termination Date upon 10-days prior written
notice to the Consultant. 
 b. Termination of this Agreement shall not affect (i) the Company’s obligation to pay for Services
previously rendered by the Consultant or expenses reasonably incurred by the Consultant for which the Consultant is entitled to reimbursement under Section 3; (ii) the Consultant’s obligation to deliver all deliverables and/or work
product (“Deliverables”) to the Company pursuant to the Services performed, as applicable; or (iii) the Consultant’s continuing obligations to the Company under Sections 5, 6, 7 and 8. 

3. PAYMENTS. 

a. Compensation. 
 i.
Compensation due under this Agreement is set forth in a Statement of Work. 
 ii. The Consultant must submit invoices for completed
Services to Company that: (1) itemize in reasonable detail the Services performed, and (2) indicate dates and hours worked on such dates by the Consultant. 

iii. Unless expressly provided for in the SOW, time spent traveling will not be deemed time spent performing Services and will not be billed
to the Company, except to the extent Services are performed while traveling. 
 iv. Company shall pay undisputed invoices within thirty
(30) days after Company’s receipt of an acceptable invoice from the Consultant. 
 v. Except as set forth in any amendment to
this Agreement, the Consultant shall not be entitled to any other compensation or benefits for the Services. 

 b. Expenses. 

i. The Company will reimburse the Consultant for reasonable expenses incurred in the performance of the Services to the extent such expenses
are set forth in an SOW, or have been approved in advance and in writing by the Company. The Consultant will use commercially reasonable efforts to minimize reimbursable expenses. Travel expenses shall be reimbursed at cost and shall conform to the
following limits unless otherwise approved by the Company in advance and in writing:
  

			
	 Description
	  	 Limit

	Air Travel	  	Coach, unless pre-approved by Company at level of Chief Business Officer or higher
	Lodging	  	$300/night
	Meals	  	$100/night
	Rental Car/Taxi	  	$100/day
	Personal auto	  	Reimbursed at the legal rate established by the US Internal Revenue Service

 Entertainment expenses will not be reimbursed by the Company. The Consultant must provide copies of receipts for any single
expense incurred greater than twenty five dollars (US $25.00). Approved expenses will be reimbursed within thirty (30) days of the Company’s receipt of invoices with supporting receipts. 

ii. The Consultant is expected to arrange all approved travel through the Company’s designated agent Altour International
(“Altour”) by calling 212-897-5147 or emailing Christine Coleman at christine.coleman@altour.com. The Consultant must indicate that the Consultant is not a Company employee and provide Altour with a credit card for all travel
reservations. Altour shall book reservations that conform to Company’s travel policy. If the Consultant is unable to arrange travel through Altour, the Consultant must receive the Company representative’s approval in writing prior to
arranging her own travel. 
 c. No Vesting of Equity Compensation. In consideration of the foregoing, the Consultant agrees that all
vesting under outstanding equity grants to the Consultant granted prior to the date of this Agreement shall terminate automatically as of the date that the Consultant ceased to be an employee of the Company and nothing in this Agreement or any SOW,
nor the Services provided hereunder or thereunder, shall act to extend or continue vesting of such equity compensation. 
 4.
RELATIONSHIP OF THE PARTIES – INDEPENDENT CONTRACTORS. 

a. Notwithstanding any provision of this Agreement to the contrary, the Consultant is and shall at all times be an independent contractor and
not an employee, agent, partner, or joint venturer of the Company. The Consultant shall have no right under this Agreement, or as a result of its consulting services to the Company, to participate in any other employee, retirement, insurance or
other benefit program of the Company, nor will the Company make any deductions from the Consultant’s compensation for taxes, the payment of which shall be solely the Consultant’s responsibility. The parties agree and acknowledge that there
is no attorney client relationship between the Consultant and the Company. For the avoidance of doubt, the Consultant shall not be asked, and shall not provide, any legal services or legal advice to the Company as part of the Services. 

b. The Consultant shall pay when due any and all taxes incurred as a result of her compensation hereunder, including without limitation,
estimated taxes, and if requested by the Company, provide the Company with proof of payment. The Consultant further agrees to indemnify the Company and hold it harmless to the extent of any obligation imposed on the Company: (i) to pay
withholding taxes or similar items; or (ii) resulting from the Consultant being determined not to be an independent contractor. 

5. REPRESENTATIONS AND WARRANTIES. 

  

					
	Heather D. Turner	  	Consulting Agreement	  	 Page
 2
 of 9

 a. The Consultant makes the following representations and warranties: 

i. Neither this Agreement nor the performance of the Services conflicts with or violates any obligation of the Consultant or right of any
third party; 
 ii. All licenses or certifications necessary to perform the Services have been obtained; 

iii. All applicable laws will be complied with in the performance of the Services including, as applicable but without limitation, the
Federal Food, Drug, and Cosmetic Act, including its implementing regulations; the Health Insurance Portability and Accountability Act and all other privacy laws; 

iv. The Consultant: (a) is not under investigation by the U.S. Food and Drug Administration for debarment action or is presently
debarred under the Federal Food, Drug and Cosmetic Act, as amended, the Generic Drug Enforcement Act of 1992 (21 U.S.C. 301 et seq.), or is listed on the HHS/OIG List of Excluded Individuals/Entities or the System for Awards Management or
(b) has not violated, or is not under investigation for violating, any state or federal health care programs or has not violated any such state or federal health care programs or any federal or state anti-kickback laws or regulations; and 

v. The Consultant will notify the Company immediately upon gaining knowledge that any of the foregoing ceases to be true. 

6. NONDISCLOSURE OF CONFIDENTIAL INFORMATION. 

a. The Consultant recognizes and acknowledges that certain knowledge and information which she will acquire or develop relating to the
business of the Company, including, without limitation, any financial information, business plans, clinical and product development plans, strategies, business forecasts, sales and merchandising materials, patent disclosures, patent applications,
structures, models, techniques, know-how, trade secrets, processes, compositions, formulations, compounds and apparatus relating to the same and other proprietary information related to the current, future and proposed products and services of the
Company (collectively, “Confidential Information”) are the valuable property of the Company. For purposes of this Agreement, Confidential Information of the Company also includes information disclosed to the Consultant by
third parties who are consulting or collaborating with the Company in connection with the Consultant’s performance of the Services. 

b. The Consultant shall not be obligated to treat as confidential, any Confidential Information that (i) was publicly known at the time
of disclosure to the Consultant, (ii) became publicly known or available thereafter other than by means in violation of this Agreement or any other duty owed to the Company by the Consultant, or (iii) was lawfully disclosed to the
Consultant by a third party. 
 c. In the event a court or governmental agency legally compels the Consultant to disclose Confidential
Information, the Consultant shall promptly inform the Company of the compelled disclosure, so that the Company may seek a protective order or other remedy or waive compliance with this Agreement, or both. The Consultant shall limit any compelled
disclosure of Confidential Information to that legally required. 
 d. The Consultant agrees not to use the Confidential Information for
any purpose other than in connection with the Consultant’s performance of the Services. 
 e. The Consultant covenants and agrees
that, without the prior written consent of the Company, the Consultant will not disclose the Confidential Information to third parties at any time. Any such authorized disclosures shall only be as necessary to perform the Services, and only to third
parties who are bound by written agreements with the Consultant to maintain the Confidential 

  

					
	Heather D. Turner	  	Consulting Agreement	  	 Page
 3
 of 9

 
Information in confidence. All such agreements shall contain confidentiality provisions at least as protective as the provisions contained in this Agreement. 

f. The Consultant agrees not to disclose to the Company, or use in connection with the Consultant’s efforts for the Company, any
Confidential Information belonging to any third party, including without limitation the Consultant’s prior employers, or any prior inventions made by her or them and which the Company is not otherwise legally entitled to learn of or use. 

g. Upon termination of the Services hereunder, or at the Company’s request at any other time, the Consultant agrees to promptly deliver
to the Company, all Confidential Information in her possession that is in written or other tangible form (together with all copies or duplicates thereof, including without limitation computer files), and all other property, materials or
equipment that belong to the Company, its customers, its prospects or its suppliers. 
 7. INTELLECTUAL
PROPERTY. 
 a. “Intellectual Property” includes any and all new or useful art,
discovery, improvement, technical development, or invention, whether or not patentable and all related know-how, designs, trademarks, formulae, processes, manufacturing techniques, trade secrets, ideas, artworks, software or other copyrightable or
patentable work, that the Consultant, solely or jointly with others, makes, conceives or reduces to practice that resulted from the Consultant’s Services for the Company under this Agreement or any services performed by the Consultant under any
prior consulting arrangement or agreement with the Company, whether oral or written (a “Prior Agreement”). All right, title and interest of every kind and nature whatsoever in and to the Intellectual Property made, discussed,
developed, secured, obtained or learned by the Consultant during the term of this Agreement or any Prior Agreement, or the 60-day period immediately following termination of this Agreement, are hereby assigned to the Company, and shall be the sole
and exclusive property of the Company for any purposes or uses whatsoever, and shall be disclosed promptly by the Consultant to the Company. 

b. The Consultant shall assist the Company in any reasonable manner to obtain and enforce for the Company’s benefit any patents,
copyrights and other property rights in any and all countries, with respect to any Intellectual Property, and the Consultant agrees to execute, when requested, patent, copyright or similar applications and assignments to the Company and any other
lawful documents deemed necessary by the Company to carry out the purposes of this Agreement. In the event that the Company is unable for any reason to secure the Consultant’s signature to any document required to apply for or execute any
patent, copyright or other applications with respect to any Intellectual Property (including but not limited to improvements, renewals, extensions, continuations, divisions or continuations in part thereof), after a written demand is made upon the
Consultant (which shall refer to the provisions of this paragraph), the Consultant hereby irrevocably designates and appoints the Company and her duly authorized officers and agents as the Consultant’s agents and attorneys-in-fact to act for
and on the Consultant’s behalf and instead of the Consultant, to execute and file any such application and to do all other lawfully permitted acts to further the prosecution and issuance of patents, copyrights, mask works or other rights
thereon with the same legal force and effect as if executed by the Consultant. 
 8. NON-SOLICITATION.

 a. The Consultant agrees that, without the prior written consent of the Company, the Consultant will not directly or indirectly during
the term of this Agreement (a) call upon, solicit, divert or take away or attempt to solicit, divert or take away any of the customers, business or patrons of the Company; or (b) solicit or attempt to solicit for employment any person who
is an employee of or consultant to the Company or who was an employee of or consultant to the Company at any time during the twelve (12) month period immediately prior to the date of solicitation. 

  

					
	Heather D. Turner	  	Consulting Agreement	  	 Page
 4
 of 9

 b. The parties acknowledge that the foregoing restrictions are necessary and reasonable in scope
and duration and are a material inducement to the Company to execute, deliver and perform its obligations arising under or pursuant to this Agreement. 

9. NO EMPLOYMENT OF ASSISTANTS OR
SUBCONTRACTING. Except as expressly authorized in a Statement of Work, the Consultant shall not employ assistants to aid her in the performance of the Services or subcontract any of the Services to a third party without the
advance written approval of the Company. 
 10. INDEMNIFICATION. The Consultant agrees to indemnify, defend, and hold
the Company free and harmless from all third party claims, demands, losses, costs, expenses, obligations, liabilities, damages, recoveries and deficiencies, including without limitation interest, penalties, attorneys’ fees, and costs, that the
Company may incur as a result of a material breach by the Consultant of any of its obligations hereunder. 
 11. RIGHTS
AND REMEDIES UPON BREACH. If the Consultant breaches or threatens to commit a breach of any of the provisions of Sections 5, 6, 7 and 8 (the “Protective
Representations and Covenants”), the Consultant agrees that such breach or threatened breach would cause irreparable injury to the Company and that money damages would not provide an adequate remedy to the Company. Accordingly, the
Company may seek applicable injunctive relief and/or a decree for specific performance, and such other and further equitable or other relief as may be proper. 

12. ACKNOWLEDGMENT REGARDING SECURITIES LAWS. The Consultant acknowledges
that the Company’s Confidential Information may represent material, non-public information of the Company, and that the Consultant is aware of the restrictions imposed by the United States securities laws on the purchase or sale of securities
by any person who has received material, non-public information from the issuer of such securities and on the communication of such information to any other person when it is reasonably foreseeable that such other person is likely to purchase or
sell such securities in reliance upon such information. 
 13. MISCELLANEOUS. 

a. This Agreement shall be governed by the laws of California, without regard to any provisions relating to conflict of laws among different
jurisdictions. 
 b. Any dispute or controversy arising out of or relating to any interpretation, construction, performance or breach of
this Agreement shall be settled by arbitration before a single neutral arbitrator to be held in San Diego County, California, in accordance with the current National Rules for the Resolution of Employment Disputes of the American Arbitration
Association (“AAA”). The arbitrator may grant injunctions or other relief, and may award the prevailing party its counsel fees and expenses in accordance with applicable law. The decision of the arbitrator shall be final,
conclusive and binding on the parties. Judgment may be entered on the arbitrator’s decision in any court of competent jurisdiction. Notwithstanding the AAA’s rules, the parties may take discovery in accordance with Section 1283.05 of
the California Code of Civil Procedure. Nothing in this paragraph shall prohibit or limit the parties from seeking provisional remedies (including without limitation injunctive relief) in lieu of or in addition to arbitration at any time directly
from a court of competent jurisdiction, pursuant to California Code of Civil Procedure Section 1281.8 or any similar statute of an applicable jurisdiction. 

c. This Agreement, along with that certain Separation and Consulting Agreement, is the entire agreement of the parties with respect to the
Services and supersedes any prior or contemporaneous agreements between the parties with respect to the subject matter of this Agreement; provided, however, that this Agreement does not alter or diminish any obligations of the Consultant
associated with the Consultant’s former employment relationship with Company. For clarity, any and all 

  

					
	Heather D. Turner	  	Consulting Agreement	  	 Page
 5
 of 9

 
obligations arising under the Proprietary Information and Technology Agreement, Insider Trading Policy, IT User Agreement, Code of Business Conduct/Ethics, Quality Manual, ESPP Acknowledgment
form, and other similar agreements or policies, as applicable, between the Consultant and Company are not modified or superseded by this Agreement. Rather, the obligations set forth in this Agreement are in addition to such prior obligations. 

d. This Agreement may be amended only in writing by the Company and the Consultant and their respective permitted successors and assigns.

 e. The Consultant may not assign, subcontract or otherwise delegate its obligations under this Agreement without the Company’s
prior written consent. Subject to the foregoing, this Agreement will be binding upon and inure to the benefit of the parties and their respective heirs, legal representatives, successors and assigns. 

f. Either party’s failure to enforce any right resulting from a breach of any provision of this Agreement shall not operate or be
construed as a waiver of any other or subsequent breach by the other party. 
 g. Notices from one party to the other will be in writing
and will be delivered to the applicable address set forth below, or at such other address as either party may specify in writing to the other. Notices shall be sent by reputable express international courier, personal delivery, by fax (with
confirmation of receipt required), or by other means of delivery requiring a written acknowledged receipt. 
  

			
	Company:	  	 Orexigen Therapeutics, Inc.
 3344 N. Torrey
Pines Court, Suite 200
 La Jolla, CA 92037
 Attn: Chief
Financial Officer
 Fax: 858-875-8650

	
	 With a copy (which alone will not constitute notice) to:

		
		  	 Orexigen Therapeutics, Inc.
 3344 N. Torrey
Pines Court, Suite 200
 La Jolla, CA 92037
 Attn: General
Counsel
 Fax: 858-875-8650

		
	Consultant:	  	 Heather D. Turner
 419 Princeton Rd.

San Mateo, CA 94402
 Fax: (provide, if applicable)

 h. If any of the provisions of this Agreement are found to be invalid under an applicable statute or
rule of law, they are to be enforced to the maximum extent permitted by law and beyond such extent are to be deemed omitted from this Agreement, without affecting the validity of any other provision of this Agreement. 

i. This Agreement may be executed in counterparts, each of which will be deemed an original and all of which together shall constitute one
and the same instrument. A facsimile, PDF or any other type of copy of an executed version of this Agreement signed by a party is binding upon the signing party to the same extent as the original of the signed Agreement, and may be delivered
electronically. 
 j. The covenants, representations and warranties in this Agreement shall survive the termination of this Agreement. 

  

					
	Heather D. Turner	  	Consulting Agreement	  	 Page
 6
 of 9

 k. The Consultant hereby acknowledges that the Consultant has been encouraged to consult with
legal counsel (at the Consultant’s own expense) prior to executing this Agreement. 
 [SIGNATURE PAGE FOLLOWS] 

  

					
	Heather D. Turner	  	Consulting Agreement	  	 Page
 7
 of 9

 Having understood and agreed to the foregoing, the Company and the Consultant have signed this
Agreement as of the Effective Date. 
  

									
	OREXIGEN THERAPEUTICS, INC.	 		 	HEATHER D. TURNER
					
	By:	 	 /s/ Michael Narachi
	 		 	By:	 	 /s/ Heather D. Turner

					
	Name:	 	 Michael Narachi
	 		 	Name:	 	 Heather D. Turner

					
	Title:	 	 CEO
	 		 	Title:	 	 SVP, General Counsel and Secretary

  

					
	Heather D. Turner	  	Consulting Agreement	  	 Page
 8
 of 9

 EXHIBIT A 

STATEMENT OF WORK 
 The
Consultant shall, at times agreeable to the Consultant and as requested by the Company, make herself available and consult with the Company with respect to the Services specifically defined in this Statement of Work (“SOW”),
or as otherwise requested and mutually agreed upon in advance with Company. 
 Description of Services 

The Consultant agrees to provide non-legal Services to the Company, including (a) providing factual information, upon request, related to the
Consultant’s historical knowledge of Company activities and (b) providing transitional support related to outstanding projects, tasks and relationships. For the avoidance of doubt, the Consultant shall not be asked, and shall not provide,
any legal services or legal advice to the Company as part of the Services. 
 The Consultant will not be required to provide Services for more than [*...***...] hours in any month during the Term, and Consultant will not be required to report to the Company’s offices during the Term (as defined below). 

Term 
 The term of this SOW begins on the Effective
Date of the Agreement and shall continue until March 31, 2016, unless terminated early pursuant to Section 2 of the Agreement (the “Term”).  

Compensation 
 Fees: The Consultant
shall be paid [...***...] U.S. dollars ($[...***...]) per hour for performed Services in accordance with the terms set forth in Section 3 of the Agreement. 

Expenses: The Consultant shall be reimbursed for reasonably, incurred expenses in accordance with the terms set forth in
Section 3.b of the Agreement. 
 Not to Exceed Amount: Total compensation under this SOW shall not exceed [...***...] U.S.
dollars ($[...***...]) without the advance written approval of the Company. 
 Primary Party Contacts 

The following individual(s) are the primary contacts for purposes of this SOW: 

 

							
	For Consultant:	  	For Company:
				
	Name:	  	Heather Turner	  	Name:	  	To be provided.
				
	Phone:	  	408-921-3166	  	Phone:	  	To be provided.
				
	Email:	  	turnerhd73@yahoo.com	  	Email:	  	To be provided.

  
 * ***Confidential Treatment Requested 
  

					
	Heather D. Turner	  	Consulting Agreement	  	 Page
 9
 of 9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00248-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00248-of-00352.parquet"}]]